检索历史 清除

难治性全身型重症肌无力（gMG）是对常规免疫治疗药物反应有限、不能耐受药物不良反应或病情易反复、难以达到治疗目标的一类疾病。为了便于在临床研究中对其诊断标准形成共识，为难治性gMG的诊疗方案及新型靶向药物的规范使用提供参考依据，中国罕见病联盟神经罕见病专业委员会、中国罕见病联盟重症肌无力协作组和中华医学会神经病学分会神经肌肉病学组的相关专家基于当前最佳循证证据，结合我国的国情，讨论并制订了中国难治性gMG诊断和治疗专家共识（2024版），内容包括难治性gMG的诊断标准、危险因素、抗体复核、合并疾病鉴别及治疗等。

Refractory generalized myasthenia gravis (gMG) is a subtype of myasthenia gravis that exhibits limited response to conventional immunosuppressive drugs or has a tendency for recurrence, thereby posing challenges in achieving treatment goals. To establish the consensus on diagnostic criteria and treatment protocols of refractory gMG, experts from the Neurology Society of China Alliance for Rare Diseases, Chinese Myasthenia Gravis Collaboration Group and Chinese Society of Neuromuscular Disease have developed this consensus. The consensus consists of diagnostic criteria, risk factors, antibody revalidation, identification of comorbidities, and treatment approaches for refractory gMG.